4lvd: Difference between revisions

No edit summary
No edit summary
Line 1: Line 1:
{{STRUCTURE_4lvd|  PDB=4lvd  |  SCENE=  }}
==Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)==
===Fragment-based Identification of Amides Derived From trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)===
<StructureSection load='4lvd' size='340' side='right' caption='[[4lvd]], [[Resolution|resolution]] 1.75&Aring;' scene=''>
{{ABSTRACT_PUBMED_24021463}}
== Structural highlights ==
<table><tr><td colspan='2'>[[4lvd]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LVD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4LVD FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1EB:N-(4-NITROPHENYL)CYCLOPROPANECARBOXAMIDE'>1EB</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4lv9|4lv9]], [[4lva|4lva]], [[4lvb|4lvb]], [[4lvf|4lvf]], [[4lvg|4lvg]], [[4m6p|4m6p]], [[4m6q|4m6q]]</td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">NAMPT, PBEF, PBEF1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])</td></tr>
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Nicotinamide_phosphoribosyltransferase Nicotinamide phosphoribosyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.4.2.12 2.4.2.12] </span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4lvd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4lvd OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4lvd RCSB], [http://www.ebi.ac.uk/pdbsum/4lvd PDBsum]</span></td></tr>
</table>
== Function ==
[[http://www.uniprot.org/uniprot/NAMPT_HUMAN NAMPT_HUMAN]] Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway (By similarity).
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Potent, 1H-pyrazolo[3,4-b]pyridine-containing inhibitors of the human nicotinamide phosphoribosyltransferase (NAMPT) enzyme were identified using structure-based design techniques. Many of these compounds exhibited nanomolar antiproliferation activities against human tumor lines in in vitro cell culture experiments, and a representative example (compound 26) demonstrated encouraging in vivo efficacy in a mouse xenograft tumor model derived from the A2780 cell line. This molecule also exhibited reduced rat retinal exposures relative to a previously studied imidazo-pyridine-containing NAMPT inhibitor. Somewhat surprisingly, compound 26 was only weakly active in vitro against mouse and monkey tumor cell lines even though it was a potent inhibitor of NAMPT enzymes derived from these species. The compound also exhibited only minimal effects on in vivo NAD levels in mice, and these changes were considerably less profound than those produced by an imidazo-pyridine-containing NAMPT inhibitor. The crystal structures of compound 26 and the corresponding PRPP-derived ribose adduct in complex with NAMPT were also obtained.


==Function==
Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,Zheng X, Bair KW, Bauer P, Baumeister T, Bowman KK, Buckmelter AJ, Caligiuri M, Clodfelter KH, Feng Y, Han B, Ho YC, Kley N, Li H, Liang X, Liederer BM, Lin J, Ly J, O'Brien T, Oeh J, Oh A, Reynolds DJ, Sampath D, Sharma G, Skelton N, Smith CC, Tremayne J, Wang L, Wang W, Wang Z, Wu H, Wu J, Xiao Y, Yang G, Yuen PW, Zak M, Dragovich PS Bioorg Med Chem Lett. 2013 Oct 15;23(20):5488-97. doi:, 10.1016/j.bmcl.2013.08.074. Epub 2013 Aug 22. PMID:24021463<ref>PMID:24021463</ref>
[[http://www.uniprot.org/uniprot/NAMPT_HUMAN NAMPT_HUMAN]] Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway (By similarity).  


==About this Structure==
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
[[4lvd]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LVD OCA].
</div>


==Reference==
==See Also==
<ref group="xtra">PMID:024021463</ref><references group="xtra"/><references/>
*[[Phosphoribosyltransferase|Phosphoribosyltransferase]]
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Nicotinamide phosphoribosyltransferase]]
[[Category: Nicotinamide phosphoribosyltransferase]]
[[Category: Bravo, B.]]
[[Category: Bravo, B]]
[[Category: Brien, T O.]]
[[Category: Brien, T O]]
[[Category: Dragovich, P S.]]
[[Category: Dragovich, P S]]
[[Category: Feng, Y.]]
[[Category: Feng, Y]]
[[Category: Giannetti, A M.]]
[[Category: Giannetti, A M]]
[[Category: Gunzner-Toste, J.]]
[[Category: Gunzner-Toste, J]]
[[Category: Ho, Y.]]
[[Category: Ho, Y]]
[[Category: Hua, R.]]
[[Category: Hua, R]]
[[Category: Liederer, B M.]]
[[Category: Liederer, B M]]
[[Category: Liu, Y.]]
[[Category: Liu, Y]]
[[Category: Oeh, J.]]
[[Category: Oeh, J]]
[[Category: Sampath, D.]]
[[Category: Sampath, D]]
[[Category: Shen, Y.]]
[[Category: Shen, Y]]
[[Category: Skelton, N.]]
[[Category: Skelton, N]]
[[Category: Wang, C.]]
[[Category: Wang, C]]
[[Category: Wang, L.]]
[[Category: Wang, L]]
[[Category: Wang, W.]]
[[Category: Wang, W]]
[[Category: Wu, H.]]
[[Category: Wu, H]]
[[Category: Xiao, Y.]]
[[Category: Xiao, Y]]
[[Category: Yuen, P.]]
[[Category: Yuen, P]]
[[Category: Zak, M.]]
[[Category: Zak, M]]
[[Category: Zhao, G.]]
[[Category: Zhao, G]]
[[Category: Zhao, Q.]]
[[Category: Zhao, Q]]
[[Category: Zheng, X.]]
[[Category: Zheng, X]]
[[Category: Transferase]]
[[Category: Transferase]]
[[Category: Transferase-transferase inhibitor complex]]
[[Category: Transferase-transferase inhibitor complex]]

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA